RU2013113184A - Комбинированное лечение розацеа - Google Patents
Комбинированное лечение розацеа Download PDFInfo
- Publication number
- RU2013113184A RU2013113184A RU2013113184/15A RU2013113184A RU2013113184A RU 2013113184 A RU2013113184 A RU 2013113184A RU 2013113184/15 A RU2013113184/15 A RU 2013113184/15A RU 2013113184 A RU2013113184 A RU 2013113184A RU 2013113184 A RU2013113184 A RU 2013113184A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- brimonidine
- oxymetazoline
- composition
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims abstract 33
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims abstract 30
- 238000000034 method Methods 0.000 claims abstract 25
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims abstract 17
- 229960003679 brimonidine Drugs 0.000 claims abstract 17
- 229960001528 oxymetazoline Drugs 0.000 claims abstract 16
- 239000000203 mixture Substances 0.000 claims abstract 13
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims abstract 4
- 206010015150 Erythema Diseases 0.000 claims abstract 4
- 241001303601 Rosacea Species 0.000 claims abstract 4
- 206010043189 Telangiectasia Diseases 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 229960001724 brimonidine tartrate Drugs 0.000 claims abstract 4
- 231100000321 erythema Toxicity 0.000 claims abstract 4
- 201000004700 rosacea Diseases 0.000 claims abstract 4
- 208000009056 telangiectasis Diseases 0.000 claims abstract 4
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims abstract 3
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000000699 topical effect Effects 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38726010P | 2010-09-28 | 2010-09-28 | |
| US61/387,260 | 2010-09-28 | ||
| US13/232,134 | 2011-09-14 | ||
| US13/232,134 US20120082625A1 (en) | 2010-09-28 | 2011-09-14 | Combination treatment for rosacea |
| PCT/US2011/053440 WO2012047645A2 (en) | 2010-09-28 | 2011-09-27 | Combination treatment for rosacea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013113184A true RU2013113184A (ru) | 2014-11-10 |
Family
ID=45890007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013113184/15A RU2013113184A (ru) | 2010-09-28 | 2011-09-27 | Комбинированное лечение розацеа |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20120082625A1 (enExample) |
| EP (1) | EP2621497A4 (enExample) |
| JP (1) | JP2013538853A (enExample) |
| KR (1) | KR20140056130A (enExample) |
| CN (1) | CN103354743A (enExample) |
| AU (1) | AU2011312518A1 (enExample) |
| BR (1) | BR112013007343A2 (enExample) |
| CA (1) | CA2811783A1 (enExample) |
| MX (1) | MX2013003638A (enExample) |
| RU (1) | RU2013113184A (enExample) |
| WO (1) | WO2012047645A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766973C1 (ru) * | 2021-10-05 | 2022-03-16 | Татьяна Сергеевна Русина | Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| CA2819633C (en) * | 2010-12-03 | 2019-04-23 | Allergan, Inc. | Pharmaceutical cream compositions and methods of use |
| AU2012217858A1 (en) | 2011-02-15 | 2013-09-05 | Allergan, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| CN104666239A (zh) * | 2013-11-27 | 2015-06-03 | 杭州赛利药物研究所有限公司 | 酒石酸溴莫尼定凝胶及其制备方法 |
| AU2016222902A1 (en) * | 2015-02-24 | 2017-08-31 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
| US9989950B2 (en) | 2015-07-17 | 2018-06-05 | General Electric Company | Systems and methods for generating control logic |
| FR3041537B1 (fr) * | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee. |
| EP3434271B1 (en) * | 2016-03-22 | 2020-08-26 | Doris Maria Hexsel | Use of pharmaceutical composition for the treatment of poikiloderma of civatte |
| EP3476393A4 (en) * | 2016-06-28 | 2019-07-17 | Doris Maria Hexsel | USE OF AN ACTIVE AGENT FOR THE TREATMENT OF TELANGIEKTATISCHEM MELASMA |
| WO2018065546A1 (en) * | 2016-10-07 | 2018-04-12 | Micreos Human Health B.V. | Vasoconstricitve and antibacterial combination treatment for rosacea |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| CA2567401C (en) * | 2004-05-25 | 2013-11-12 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| EP2818184B1 (en) * | 2007-11-16 | 2018-10-31 | Allergan, Inc. | Compositions and methods for treating Purpura |
| FR2942138A1 (fr) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
-
2011
- 2011-09-14 US US13/232,134 patent/US20120082625A1/en not_active Abandoned
- 2011-09-27 BR BR112013007343A patent/BR112013007343A2/pt not_active IP Right Cessation
- 2011-09-27 KR KR1020137010904A patent/KR20140056130A/ko not_active Ceased
- 2011-09-27 CA CA2811783A patent/CA2811783A1/en not_active Abandoned
- 2011-09-27 JP JP2013531717A patent/JP2013538853A/ja active Pending
- 2011-09-27 EP EP11831290.9A patent/EP2621497A4/en not_active Withdrawn
- 2011-09-27 RU RU2013113184/15A patent/RU2013113184A/ru not_active Application Discontinuation
- 2011-09-27 MX MX2013003638A patent/MX2013003638A/es unknown
- 2011-09-27 WO PCT/US2011/053440 patent/WO2012047645A2/en not_active Ceased
- 2011-09-27 AU AU2011312518A patent/AU2011312518A1/en not_active Abandoned
- 2011-09-27 CN CN2011800470779A patent/CN103354743A/zh active Pending
-
2013
- 2013-12-09 US US14/100,450 patent/US20140100232A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/797,519 patent/US20150313894A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766973C1 (ru) * | 2021-10-05 | 2022-03-16 | Татьяна Сергеевна Русина | Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011312518A1 (en) | 2013-04-18 |
| WO2012047645A3 (en) | 2012-05-31 |
| US20140100232A1 (en) | 2014-04-10 |
| CA2811783A1 (en) | 2012-04-12 |
| US20150313894A1 (en) | 2015-11-05 |
| EP2621497A2 (en) | 2013-08-07 |
| BR112013007343A2 (pt) | 2016-07-05 |
| EP2621497A4 (en) | 2014-03-05 |
| MX2013003638A (es) | 2013-08-29 |
| WO2012047645A2 (en) | 2012-04-12 |
| KR20140056130A (ko) | 2014-05-09 |
| US20120082625A1 (en) | 2012-04-05 |
| JP2013538853A (ja) | 2013-10-17 |
| CN103354743A (zh) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013113184A (ru) | Комбинированное лечение розацеа | |
| JP2013538853A5 (enExample) | ||
| RU2013113188A (ru) | Комбинированное лечение дерматологических состояний | |
| EA201990846A1 (ru) | СОЕДИНЕНИЯ БЕНЗО[b]ТИОФЕНА КАК АГОНИСТЫ STING | |
| UA114351C2 (uk) | Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| EA201390626A1 (ru) | Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций | |
| EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
| AU2010313643A1 (en) | Methods of treating or preventing acute erythema | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| TR201900542T4 (tr) | Ağrı ve/veya enflamasyon tedavisi için bileşimler. | |
| WO2009053741A3 (en) | Novel formulation | |
| BR112014000876A2 (pt) | composições em gel de oximetazolina e métodos de uso | |
| MX2011012143A (es) | Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas. | |
| RU2013125042A (ru) | Способ предотвращения или лечения опухоли кожи | |
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| RU2015143409A (ru) | Композиции для местного нанесения, содержащие биматопрост, и способы стимуляции роста волос с их помощью | |
| EA201492091A1 (ru) | Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину | |
| MX343205B (es) | Peptidomiméticos de horquilla beta como antagonistas de cxc4. | |
| EA200702414A1 (ru) | Использование поглотителей свободных радикалов для защиты и обработки кожи и волос, повреждённых вследствие химиотерапии | |
| EA201590546A1 (ru) | Способы лечения заболеваний, связанных с волосами | |
| WO2009106715A3 (fr) | Peptide derive d'une proteine de la famille des aquaporines | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| RU2014119919A (ru) | Способ лечения капиллярных гемангиом | |
| WO2013010707A3 (de) | Leistungsgesteigerte wirkstoffkombination und haarbehandlungsmittel gegen schuppen i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160809 |